Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer
JAMA Oncol
.
2020 Jul 1;6(7):1115-1116.
doi: 10.1001/jamaoncol.2020.0637.
Authors
Serban Ghiorghiu
1
,
Pralay Mukhopadhyay
2
,
Cristian Massacesi
2
Affiliations
1
AstraZeneca, Cambridge, United Kingdom.
2
AstraZeneca, Gaithersburg, Maryland.
PMID:
32352489
DOI:
10.1001/jamaoncol.2020.0637
No abstract available
Publication types
Letter
Comment
MeSH terms
Apoptosis
Humans
Immune Checkpoint Inhibitors*
Immunotherapy
Ligands
Neoplasms* / drug therapy
Substances
Immune Checkpoint Inhibitors
Ligands